Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
|
3 Months Ended | 9 Months Ended |
---|---|---|
Sep. 30, 2012
|
Sep. 30, 2012
Segment
|
|
Organization and Summary of Significant Accounting Policies (Additional Textual) [Abstract] | ||
Number of operating business segments | 1 | |
Domestic revenue of sublingual buprenorphine formulations | $ 1,300,000,000 | |
Non-cash loss on an increase in the fair value | $ 3,673,000 | |
Iloperidone patent expiry year | 2016-10 | |
Minimum [Member]
|
||
Organization and Summary of Significant Accounting Policies (Textual) [Abstract] | ||
Royalty revenue percentage | 8.00% | |
Maximum [Member]
|
||
Organization and Summary of Significant Accounting Policies (Textual) [Abstract] | ||
Royalty revenue percentage | 10.00% |